Business
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
- Abstract from trial evaluating Alpha DaRT® in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma selected for podium presentation - - The AHNS International Conference on Head and Neck Cancer is widely recognized as one of the premier global forums dedicated to advancing head and neck oncology - - Clinical trial builds on Alpha DaRT monotherapy data generated across clinical studies in the United States, Europe, Israel,
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7VgHu6alli3.BtV2lI3Eng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMQ--/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"text","content":"- Abstract from trial evaluating Alpha DaRT® in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma selected for podium presentation -","length":208,"tagName":"p"},{"type":"text","content":"- The AHNS International Conference on Head and Neck Cancer is widely recognized as one of the premier global forums dedicated to advancing head and neck oncology -","length":164,"tagName":"p"},{"type":"text","content":"- Clinical trial builds on Alpha DaRT monotherapy data generated across clinical studies in the United States, Europe, Israel, and Japan, and marks a key milestone in the Company’s combination therapy strategy -","length":211,"tagName":"p"},{"type":"text","content":"- Head and neck cancer is the sixth most common malignancy worldwide, with elderly patients facing particularly limited treatment options and poor outcomes -","length":157,"tagName":"p"},{"type":"text","content":"JERUSALEM, May 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that an abstract entitled “Management of Locally Advanced and Metastatic Head and Neck Squamous Cell Carcinoma in Elderly Patients Using Diffusing Alpha-Emitter Radiation Therapy in Combination with Pembrolizumab” has been accepted for podium presentation at the American Head and Neck Society (“AHNS”) 12th International Conference on Head and Neck Cancer, taking place July 18-22, 2026, in Boston, Massachusetts. The presentation is scheduled to occur during the Proffered Papers session on Radiation and Adjuvant Therapies on Tuesday, July 21, 2026, 10:30 AM - 12:00 PM.","length":769,"tagName":"p"},{"type":"text","content":"The AHNS International Conference on Head and Neck Ca...